SAN.PA : Summary for SANOFI - Yahoo Finance

U.S. Markets open in 6 hrs 22 mins

Sanofi (SAN.PA)


Paris - Paris Delayed Price. Currency in EUR
Add to watchlist
75.77-0.73 (-0.95%)
As of 5:35PM CET. Market open.
People also watch
FP.PABN.PACS.PAOR.PAAI.PA
Interactive chart
  • 1d
  • 5d
  • 1m
  • 6m
  • YTD
  • 1y
  • 2y
  • 5y
  • 10y
  • Max
1d
Previous Close76.50
Open76.54
Bid71.12 x 1000
Ask71.74 x 44000
Day's Range75.38 - 76.69
52 Week Range62.50 - 79.07
Volume2,026,228
Avg. Volume2,912,339
Market Cap95.13B
Beta0.74
PE Ratio (TTM)23.25
EPS (TTM)N/A
Earnings DateN/A
Dividend & Yield3.35 (4.12%)
Ex-Dividend DateN/A
1y Target EstN/A
  • Reuters1 hour ago

    Sanofi's M&A misses frustrate some investors in drugmaker

    PARIS/DAVOS, Switzerland (Reuters) - For the last year, Sanofi's chief executive has made clear his quest for deals to help revive the fortunes of France's biggest drugmaker. Olivier Brandicourt's failure to land two big biotech acquisitions he was chasing has led to growing impatience among some investors. In an interview at the World Economic Forum in the Swiss resort of Davos this week Brandicourt defended his track record, citing an unwillingness to overpay for pricey assets and a paucity of good opportunities.

  • The Wall Street Journal11 hours ago

    [$$] Rival to EpiPen Allergy Treatment to Return to Market

    The maker of an EpiPen rival said its emergency allergy treatment would return to the market on Feb. 14, adding more competition to the market for the costly products.

  • The Wall Street Journalyesterday

    [$$] Mallinckrodt Settles Antitrust Allegations on Unlawful Drug Monopoly

    Irish drugmaker Mallinckrodt and a U.S. subsidiary will pay $100 million and agree to other conditions to settle government antitrust allegations they unlawfully prevented competition for Acthar, a drug ...